These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34958928)

  • 21. Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study.
    Zhen Y; Xu YB; Deng RY; Li M; Ma MT; Zhou ZG; Meng QJ; Gong YN; Zhao LY; Liu YB
    Comb Chem High Throughput Screen; 2024; 27(6):845-853. PubMed ID: 37282652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
    Reungwetwattana T; Cho BC; Lee KH; Pang YK; Fong CH; Kang JH; Lee YG; Lim CS; Danchaivijitr P; Lim YN; Lee Y; How SH; Geater S; Lee SS; Min YJ; Kim JH; Lee JS; Lee GW; Soo RA; Lee SY; Choi S; Ahn MJ
    J Thorac Oncol; 2023 Oct; 18(10):1351-1361. PubMed ID: 37702629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
    Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
    Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
    Park K; Jӓnne PA; Kim DW; Han JY; Wu MF; Lee JS; Kang JH; Lee DH; Cho BC; Yu CJ; Pang YK; Felip E; Kim H; Baek E; Noh YS
    Cancer; 2021 May; 127(9):1407-1416. PubMed ID: 33434335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
    Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
    Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
    Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
    Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lazertinib: on the Way to Its Throne.
    Lee J; Hong MH; Cho BC
    Yonsei Med J; 2022 Sep; 63(9):799-805. PubMed ID: 36031779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
    Ma Y; Zheng X; Zhao H; Fang W; Zhang Y; Ge J; Wang L; Wang W; Jiang J; Chuai S; Zhang Z; Xu W; Xu X; Hu P; Zhang L
    J Thorac Oncol; 2018 Jul; 13(7):968-977. PubMed ID: 29626621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
    Park S; Ku BM; Jung HA; Sun JM; Ahn JS; Lee SH; Park K; Ahn MJ
    Cancer Res Treat; 2020 Oct; 52(4):1288-1290. PubMed ID: 32599977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
    Lu S; Wang Q; Zhang G; Dong X; Yang CT; Song Y; Chang GC; Lu Y; Pan H; Chiu CH; Wang Z; Feng J; Zhou J; Xu X; Guo R; Chen J; Yang H; Chen Y; Yu Z; Shiah HS; Wang CC; Yang N; Fang J; Wang P; Wang K; Hu Y; He J; Wang Z; Shi J; Chen S; Wu Q; Sun C; Li C; Wei H; Cheng Y; Su WC; Hsia TC; Cui J; Sun Y; Ou SI; Zhu VW; Chih-Hsin Yang J
    J Thorac Oncol; 2022 Mar; 17(3):411-422. PubMed ID: 34801749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world clinical evidence of lazertinib use in acquired
    Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ; Sun JM
    Transl Lung Cancer Res; 2023 Sep; 12(9):1912-1922. PubMed ID: 37854157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
    Kim DW; Kim SW; Camidge DR; Shu CA; Marrone KA; Le X; Blakely CM; Park K; Chang GC; Patel SP; Kar G; Cooper ZA; Samadani R; Pluta M; Kumar R; Ramalingam S
    J Thorac Oncol; 2023 May; 18(5):650-656. PubMed ID: 36641093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
    Kim B; Lee J; Jang H; Lee N; Mehta J; Jang SB
    Adv Ther; 2022 Oct; 39(10):4757-4771. PubMed ID: 35962934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.